antiretroviral simplification with darunavirritonavir monotherapy in routine clinical practice safety, effectiveness, and impact on lipid profile抗逆转录病毒的简化与darunavirritonavir单一疗法安全的日常临床实践效果,对血脂的影响.pdfVIP

antiretroviral simplification with darunavirritonavir monotherapy in routine clinical practice safety, effectiveness, and impact on lipid profile抗逆转录病毒的简化与darunavirritonavir单一疗法安全的日常临床实践效果,对血脂的影响.pdf

  1. 1、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
antiretroviral simplification with darunavirritonavir monotherapy in routine clinical practice safety, effectiveness, and impact on lipid profile抗逆转录病毒的简化与darunavirritonavir单一疗法安全的日常临床实践效果,对血脂的影响

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile ´ 1,2 ´ ´ 1,2 1,2 1,2 1 1,3 Jose R. Santos *, Jose Molto , Josep M. Llibre , Eugenia Negredo , Isabel Bravo , Arelly Ornelas , Bonaventura Clotet1,4, Roger Paredes1,4 ` 1 Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 2 Universitat Autonoma de Barcelona, Barcelona, Spain, 3 Department of Econometrics, Statistics and Spanish Economy, University of Barcelona, Barcelona, Spain, 4 IrsiCaixa Foundation, Barcelona, Spain Abstract Background: Simplification of antiretroviral treatment (ART) with darunavir/ritonavir (DRV/r) monotherapy has achieved sustained suppression of plasma viral load (pVL) in clinical trials; however, its effectiveness and safety profile has not been evaluated in routine clinical practice. Methodology/Principal Findings: We performed a retrospective cohort analysis of HIV-1-infected patients who initiated DRV/r monotherapy once daily with a pVL ,50 copies/mL under ART and at least 1 subsequent follow-up visit in our clinic. The primary study endpoints were the percentage of patients with virological failure (VF, defined as 2 consecutive pVL .50 copies/mL) at week 48, and time to VF. Other causes of treatment discontinuation and changes in lipid profile were evaluated up to week 48. Ninety-two patients were followed for a median (IQR) of 73 (57–92) weeks

您可能关注的文档

文档评论(0)

118zhuanqian + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档